Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Adempas. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Riociguat (sold as Adempas), first approved Oct 8, 2013, with 1 new use approved and 0 published complete response letters.
First approved: Oct 8, 2013
Applications: 3
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $791M
First approved in the EU: Mar 27, 2014
First approved in Japan: Jan 17, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 3 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
AdempasDrugs with a new additional indication for the treatment of pulmonary arterial hypertension. · Bayer Yakuhin, Ltd. · Feb 20, 2015
Adempas, new ingredientDrugs with a new active ingredient indicated for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical… · Bayer Yakuhin, Ltd. · Jan 17, 2014 · Review report
Clinical Trials
10 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA